Toll-Like Receptors as Novel Therapeutic Targets for the Treatment of Pancreatic Cancer by Kelly D. McCall et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
20 
Toll-Like Receptors as  
Novel Therapeutic Targets for  
the Treatment of Pancreatic Cancer 
Kelly D. McCall1, Fabian Benencia1, Leonard D. Kohn2,  
Ramiro Malgor1, Anthony Schwartz2 and Frank L. Schwartz1 
1Ohio University Heritage College of Osteopathic Medicine, 
2The Interthyr Corporation, 
USA 
1. Introduction 
Toll-Like Receptors (TLRs) are critical mediators of the innate immune response and 
subsequent activation of adaptive immune responses to pathogens that invade the body. 
TLRs on immune cells are the basis of our multigenic, innate immune, inflammatory 
response to pathogenic signature molecules that cause tissue damage. Functional TLRs 
are expressed not only on immune cells, but also on non-immune cells including cancer 
cells. TLRs are critical mediators of cellular transformation, tumor progression, and 
metastasis.  
2. Toll-Like Receptors 
TLRs are pattern recognition receptors that were originally identified in immune cells and 
described to recognize pathogen-associated molecular patterns (PAMPs) and initiate an 
innate immune response and subsequent adaptive immune responses against infection or 
tissue damage. They protect mammals from pathogenic organisms, such as viruses, by 
generating an “innate immune” response to products of the pathogenic organism (Takeda et 
al., 2003). This response results in increases in genes for several inflammatory cytokines and 
chemokines, major histocompatibility (MHC) genes I and II, as well as co-stimulatory 
molecules, and is critical for the development of antigen-specific adaptive immunity 
(Takeda et al., 2003). In addition to their presence on immune cells, TLRs are also found to 
be expressed normally on multiple non-immune cell types including, but not limited to 
epithelial cells that line the digestive system, lungs, and female reproductive tract, as well as 
on pancreatic beta cells, and keratinocytes in the skin where they function to regulate 
cellular proliferation and apoptosis in response to infection and/or other damaging 
environmental insults (radiation, chemicals, etc.)(Andonegui et al., 2003; Ortega-Cava et al., 
2003; Giarratana et al., 2004; Schroder & Maurer, 2007; Nasu & Narahara, 2010; Yamasaki et 
al., 2010; Ayari et al., 2011). Regardless of cell type, TLRs recognize not only exogenous 
PAMPs, but also endogenous damage-associated molecular patterns (DAMPs) (Table 1). 
Eleven TLRs have been described in humans to date (TLR1 to TLR11) (Sato et al., 2009). 
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TLRs are located both on the cell surface and in the cytoplasm, are differentially expressed 
in different cell types under a variety of conditions and disease states, and recognize 
different PAMPs and DAMPs (Table 1).  
Perhaps two of the most well studied TLRs are TLR3 and TLR4. In non-immune cells, as is 
the case for immune cells, dsRNA can activate two distinct anti-viral response pathways by 
activating TLR3 signaling. One, coupled via the adapter molecule, Toll-IL-1 receptor (TIR) 
domain-containing adapter inducing IFN- (TRIF) (also called TIR domain-containing 
adaptor molecule-1 [TICAM-1]), i.e. (TRIF/TICAM)-1, activates IFN regulatory factor (IRF)-
3 and the production of type 1 interferons (IFN-ǂ or IFN-ǃ) via TRAF-3 (Oganesyan et al., 
2006; Schneider et al., 2006). The type 1 IFNs, acting as autocrine/paracrine ligands increase 
STAT-1 and IRF-1 activation, critical factors in expression of chemokines such as CXCL10 
and genes such as VCAM-1. Specifically, TLR3 is expressed in the endosomal membrane 
and recognizes extracellular viral dsRNA and/or its synthetic analog poly I:C. Upon 
binding to dsRNA, TLR3 becomes dimerized, and two specific tyrosine residues (Tyr759 and 
Tyr858) in the TIR domain of TLR3 become phosphorylated and are essential for dsRNA-
induced recruitment of the adaptor protein TRIF/TICAM-1 (Sarkar et al., 2004). 
Phosphatidylinositol 3-kinase (PI3K) is then recruited to the two phosphorylated tyrosine 
residues and is required for phosphorylation and activation of IRF-3. Additionally, it has 
been shown that TLR3 associates with c-Src in response to dsRNA and that c-Src is 
necessary for PI3K-dependent activation of IRF-3, although the precise role of c-Src in this 
process is currently not well understood (Johnsen et al., 2006). TRIF/TICAM-1 dissociates 
from TLR3 and forms a complex with receptor interacting protein 1 (RIP1), TRAF-3 and NF-
B activating kinase (NAK)-associated protein 1 (NAP1). The TRIF/TICAM-1/TRAF-3/RIP-
1/NAP-1 complex participates in the recruitment and activation of TBK-1 and IKK which 
phosphorylate and activate IRF-3 (Sasai et al., 2005; Hacker et al., 2006; Oganesyan et al., 
2006). Once phosphorylated IRF-3 translocates into the nucleus and together with nuclear 
factor kappa-light chain-enhancer of activated B cells (NF-κB) and AP-1 induces IFN-ǃ gene 
transcription (Sato et al., 2000). The second pathway is coupled to a different site on 
TRIF/TICAM-1 via TRAF-6 and activates NF-B and MAP Kinase pathways important in 
the production of pro-inflammatory and inflammatory cytokines, e.g. TNF-ǂ, IL-1ǃ, and IL-
6, as well as chemokines e.g. MCP-1. 
TLR4 signaling has both a MyD88-dependent and MyD88–independent mechanism when 
activated [reviewed in (Lu et al., 2008)]. There is significant homology between TLR3 and 
TLR4 IRF-3/IFN signaling (the MyD88-independent TLR4  pathway); TRIF/TICAM-1 is a 
common signaling intermediate in both signaling pathways. As is the case with dsRNA-
induced TLR3 signaling, activation of TLR4 signaling leads to TRIF/TICAM-1 recruiting 
TRAF-3 and RIP-1 which in turn leads to the recruitment and activation of TBK-1 and IKK 
(Hacker et al., 2006; Oganesyan et al., 2006; Guo & Cheng, 2007). The TRIF/TICAM-
1/TRAF-3/RIP-1/TBK-1/IKK complex phosphorylates and activates IRF-3 (Fitzgerald et 
al., 2003; Hemmi et al., 2004). Once phosphorylated IRF-3 translocates into the nucleus and 
together with NF-κB and AP-1 induces IFN-ǃ gene transcription (Sato et al., 2000). The 
MyD88-dependent pathway activates IRAK-4, IRAK-1, TRAF-6, and others to lead to the 
activation of transcription factors NF-B, AP-1, and IRF-5, which induce the expression of 
pro-inflammatory cytokines.   
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Toll-Like 
Receptor 
Predominant Cellular 
Localization 
PAMPs/DAMPs/Other 
Ligands   
Disease 
Associations 
TLR1 Plasma Membrane triacyl lipopeptides, 
modulin (phenol-solube) 
cancer, psoriasis, 
sepsis, leprosy 
TLR2 Plasma Membrane glycolipids, triacyl 
lipopeptides, heat shock 
proteins, high mobility 
group box 1 protein, rare 
LPS species (P. gingivalis), 
lipopeptides, lipoteichoic 
acid, measles 
haemagglutinin, 
mannuronic acids, 
neisseria porins, 
peptidoglycan, zymosan 
(Beta-glucan), bacterial 
fimbriae, Yersinia virulence 
factors, CMV virions, 
saturated fatty acids 
cancer, type 2 
diabetes, psoriasis, 
pre-eclampsia, 
alzheimer's, herpes 
simplex encephalitis, 
rheumatoid arthritis, 
acne vulgaris, acute 
rheumatic fever, 
asthma, 
atherosclerosis, 
chronic obstructive 
pulmonary disease, 
diabetic 
nephropathy, 
subhorrheic 
dermatitis 
TLR3 Endosomal 
Membrane 
dsRNA (self and viral),  
poly I:C 
cancer, type 1 
diabetes, herpes 
simplex encephalitis, 
Hashimoto's 
thyroiditis, virus 
associated 
autoimmune disease 
TLR4 Plasma Membrane lipopolysaccherides, 
saturated free fatty acids, 
fibrinogen, fibronectin, 
heat shock proteins, 
flavolipins, S. pneumoniae 
pneumolysin, heparan 
sulfate, hyaluronic acid, 
high mobility group box 1 
protein, MMTV envelope 
proteins, nickel,  
paclitaxel, RSV fusion 
protein, respiratory 
syncytial virus coat 
protein, mannuronic  
acid polymers,  
teichuronic acids,  
bacterial fimbriae, 
surfactant protein A, -
defensin 2 
cancer, type 2 
diabetes, toxic shock, 
ulcerative colitis, 
atherosclerosis, pre-
eclampsia, 
alzheimer's, stroke, 
rheumatoid arthritis, 
chronic obstructive 
pulmonary disorder, 
Crohn's disease, 
periodontitis, 
peripheral arterial 
disease,  
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Toll-Like 
Receptor 
Predominant Cellular 
Localization 
PAMPs/DAMPs/Other 
Ligands   
Disease 
Associations 
TLR5 Plasma Membrane flagellin cancer, psoriasis, 
systemic lupus 
erthyematosus 
TLR6 Plasma Membrane diacyl lipopeptides, 
bacterial cell wall 
components, modulin 
(phenol-soluble) 
cancer, leprosy 
(Hansen's disease), 
filarisis, asthma, 
hypersensitivity 
pneumonitis 
TLR7 Endosomal 
Membrane 
self ssRNA, ssRNA, 
bropirimine, loxoribine, 
imidazoquinoline 
cancer, systemic 
lupus 
erythematosus, 
rheumatoid arthritis, 
arthritis 
TLR8 Endosomal 
Membrane 
self ssRNA, small synthetic 
compounds, 
imidazoquinoline 
cancer, rheumatoid 
arthritis, viral 
keratitis, crimean-
congohemorrhagic 
fever 
TLR9 Endosomal 
Membrane 
self DNA, unmethylated 
CpG DNA 
allergies, asthma, 
cancer, multiple 
sclerosis, systemic 
lupus 
erythematosus, 
Graves' 
ophthalmopathy, 
crimean-
congohemorrhagic 
fever, arthritis 
TLR10 Plasma Membrane Unknown cancer, asthma, 
nephropathy, viral 
keratitis 
Table 1. Toll-Like Receptors; Cellular Localization, Agonists, and Disease Associations 
3. TLRs, chronic inflammation, and cancer 
Overwhelming evidence suggests that chronic inflammation is crucial to the onset and 
progression of a multiplicity of human cancers, including pancreatic cancer (Kuper et al., 
2000; Garcia et al., 2004; von Hafe et al., 2004; Berstein, 2005; Otake et al., 2005; Lu et al., 
2006). The exact link between chronic inflammation and carcinogenesis is unclear, however 
many studies have shown that pro-inflammatory cytokines (TNF-ǂ, IL-6, IL-1, etc.) are 
important for the proliferation, survival, metastasis, and escape from immune surveillance 
of many of these cancers (Garcea et al., 2005; Lu et al., 2006), and have identified nuclear 
factor-ĸB (NF-ĸB) as a key modulator of inflammation-induced carcinogenesis (Chen et al., 
1995; Guttridge et al., 1999; Hinz et al., 1999; Perkins, 2000; Coussens & Werb, 2002; Esposito 
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et al., 2002; Ghosh & Karin, 2002; Karin et al., 2002; Karin & Lin, 2002; Li & Verma, 2002; 
O'Hanlon et al., 2002; Alexiou et al., 2003; Chen et al., 2003; Furbert-Harris et al., 2003; Lin & 
Karin, 2003; Greten et al., 2004; Huber et al., 2004; Luo et al., 2004; Niu et al., 2004; Pikarsky 
et al., 2004; Stoffel et al., 2004; Heyninck & Beyaert, 2005; Preciado et al., 2005; Yang et al., 
2005a). Chronic inflammation as a result of disease, microbial infection, and/or obesity is an 
important risk factor for the development of a variety of cancers (Khatami; Kuper et al., 
2000; Calle & Kaaks, 2004; Khatami, 2011) (Table 2). Chronic inflammation is thought to 
induce malignant transformation via activation of oncogenes, induction of 
immunosuppression, and inhibition of tumor suppressors.  
It is now recognized that TLRs are important in development of carcinogenesis and tumor 
progression. The chronic inflammatory state observed in autoimmune disease, microbial 
infection, and obesity is mediated via activation of TLR signaling on both immune and non-
immune cells. TLRs on immune cells recognize PAMPs and DAMPs and initiate an innate 
immune response and subsequent adaptive immune responses against infection or tissue 
damage. As part of this acute, innate immune response cytokines and chemokines are 
produced and released by the immune cells, which will subsequently upregulate TLR 
expression on non-immune cells. When this occurs, the TLRs on the non-immune cells can 
become stimulated by the same PAMPs and DAMPs that activated the TLRs on the immune 
cells, leading to very high levels of disease-causing inflammatory proteins. In a prolonged 
state of infection and/or tissue damage, sustained high levels of inflammatory proteins can 
lead to autoimmune, inflammatory diseases, and cancer in individuals with certain genetic 
and/or environmental susceptibilities (Table 1). 
Multiple TLRs have been implicated in a variety of cancers including pancreatic cancer, 
melanoma, breast cancer, prostate cancer, colorectal cancer, lung cancer, cervical cancer, liver 
cancer, etc. (McCall et al., 2007; Sato et al., 2009; Schwartz et al., 2009) (Table 3). Activation of 
TLRs on cancer cells promotes chronic inflammation which stimulates cancer cell proliferation, 
migration, tumor angiogenesis, and creates a tumor microenvironment which impairs the anti-
tumor function of the immune system allowing tumors to develop and survive. 
4. Mechanisms of TLR regulation of carcinogenesis 
4.1 Activation of TLR signaling leads to the production of cytokines that control 
growth 
As previously described, chronic TLR activation and signaling in both immune and non-
immune cells by environmental antigens are now linked to oncogenesis, tumor growth, and 
invasive spread (Schmausser et al., 2005; Kelly et al., 2006; Fukata et al., 2007; He et al., 2007; 
Ilvesaro et al., 2007; Goto et al., 2008; Kim et al., 2008; Yoneda et al., 2008; Curtin et al., 2009; 
Xie et al., 2009; Zhou et al., 2009). Activation of TLR signaling results in the activation of 
transcription factors NF-ĸB and AP-1, as well as Type I Interferon (IFN) signaling pathways 
with subsequent production of “oncogenic” cytokines, and the activation of MAPK and  
AKT signaling pathways (Figure 1). Multiple TLR-induced cytokines including TNF-ǂ, IL-1, 
IL-6, IL-8, IL-10, IL-23, etc. have been linked to oncogenesis. TLR activation also upregulates 
many growth factors such as TGF-ǃ, VEGF, CXCR4, and adhesion molecules such as ICAM-
1 (Kelly et al., 2006; He et al., 2007; Ren et al., 2007; Zhou et al., 2009). These TLR-mediated 
processes have been linked to various cancers including colon, pancreas, melanoma, breast, 
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Type of Cancer Disease/Infection Association 
Thyroid Cancer Hashimoto's Thyroiditis 
  Obesity 
Colorectal Cancer Inflammatory Bowel Disease 
  Colitis 
  Crohn's Disease 
  Obesity 
Cervical Cancer Human Papilloma Virus 
Liver Cancer Hepatitis Virus B and C 
Pancreatic Cancer Helobacter pylori 
  Obesity 
Prostate Cancer Obesity 
Hematologic Malignancies Epstein-Barr Virus 
  Cytomegalovirus 
Esophageal Adenocarcinoma Obesity 
Renal Cancer Obesity 
Endometrial Cancer Obesity 
Gallbladder Cancer Obesity 
Breast Cancer Obesity 
Gastric Cancer Epstein-Barr Virus 
  Helobacter pylori 
  Obesity 
Non-Hodgkin's Lymphoma Epstein-Barr Virus 
  Human Herpes Virus 8 
  Human Immunodeficiency Virus 
Hodgkin's Disease Epstein-Barr Virus 
Nasopharyngeal Carcinoma Epstein-Barr Virus 
Burkitt's Lymphoma Epstein-Barr Virus 
Vulvar Cancer Human Papilloma Virus 
Anus Cancer Human Papilloma Virus 
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Type of Cancer Disease/Infection Association 
Penis Cancer Human Papilloma Virus 
Head and Neck Cancer Human Papilloma Virus 
Kaposi's Sarcoma Human Herpes Virus 8 
  Human Immunodeficiency Virus 
Casteleman's Disease Human Herpes Virus 8 
Adult T-cell Leukaemia 
Human Thymus-Derived-Cell Leukaemia/Lymphoma 
Virus-1 
Bladder Cancer Schistosomes (S. haematobium) 
Table 2. Associations Between Disease, Infection, Obesity, and Cancer.  
prostate and many others (Sato et al., 2009). In addition, these cytokines also activate 
transcription factors that induce the expression of several tumor promoting and anti-
apoptotic genes which will be discussed in Section 4.2 below. 
Toll-Like Receptor Type of Cancer 
TLR1 Colon, Prostate 
TLR2 Brain, Breast, Colorectal, Gastric, Hepatocellular Carcinoma, 
Laryngeal, Lung, Melanoma, Ovarian 
TLR3 Breast, Colorectal, Hepatocellular Carcinoma, Laryngeal, Lung, 
Melanoma, Ovarian, Pancreatic 
TLR4 Bladder, Brain, Breast, Cervical, Colorectal, Gastric, Hepatocellular 
Carcinoma, Laryngeal, Lung, Melanoma, Ovarian, Pancreatic, 
Prostate 
TLR5 Cervical, Colorectal, Gastric, Ovarian 
TLR6 Hepatocellular Carcinoma, Prostate 
TLR7 Chronic Lymphocytic Leukemia, Lung 
TLR8 Lung 
TLR9 Breast, Cervical, Colorectal, Gastric, Glioma, Hepatocellular 
Carcinoma, Lung, Pancreatic, Prostate 
TLR10 Nasopharyngeal, Prostate 
TLR11 None 
Table 3. TLRs are Associated with Human Cancers 
These immune-response and tumor-associated cytokines have complex and often 
contradictory effects depending on the specific tumor, the specific TLRs activated, and the 
innate immune response to the malignancy. Indeed, the tumor microenvironment which 
includes tumor cells, tumor-derived fibroblasts, as, well as macrophages, T cells, and APCs 
each produce inflammatory cytokines forming a “milieu” which on one hand facilitates the 
differentiation and expansion of tumors and on the other tries to suppress this process. 
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Fig. 1. TLR Signaling 
The most important TLR-mediated cytokines involved in initiation and growth of malignant 
tumors appear to be tumor-derived IL-1, TNF-ǂ and IL-6. TNF-ǂ and IL-6 are potent 
activators of NF-κB pathways and JAK-STAT signaling pathways which also directly 
contribute to tumor induction and growth (See Section 4.2). TNF- and IL-6 also induce 
anti-aptotic genes such as Mcl-1, Bcl-x, cell-cycle regulators (cyclins D1/D2, c-Myc), and 
inducers of angiogenesis (VEGF) (Calo et al., 2003). TNF-ǂ in the tumor microenvironment 
also increases myeloid cell recruitment via IL-17. Importantly, IL-6 is one of the most potent 
activators of the oncogenic transcription factor STAT3 (Calo et al., 2003).  
TLR mediated IL-1 expression within tumors directly stimulates tumor growth as well as 
stimulating angiogenesis which enhances a tumor’s capacity to spread or metastasize 
(Gemma et al., 2001; Elaraj et al., 2011). Expression of IL-1 within tumors, the surrounding 
tissues, or endothelial cells is associated with aggressive growth characteristics (Elaraj et al., 
2006; Sawai et al., 2006).  
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In contrast, IL-10 is normally an inhibitory cytokine which blocks NF-κB activity and the 
JAK-STAT signaling pathway but has been shown to help certain tumors escape normal 
immune surveillance (Linehan & Goedegebuure, 2005; Perrone et al., 2008; Strauss et al., 
2009). IL-10 can induce CD4+CD25+Foxp3+ regulatory T cells (Tregs) in the tumor 
microenvironment which secrete additional IL-10 and TGFǃ, which can then suppress the 
anti-tumor function of non-Treg T cells (Linehan & Goedegebuure, 2005; Perrone et al., 2008; 
Strauss et al., 2009). 
4.2 TLR signaling activates transcription factors important for tumorigenesis 
Two of the most notorious and well-studied oncogenic transcription factors are nuclear 
factor kappa-light chain-enhancer of activated B cells (NF-B) and signal transducer and 
activator of transcription 3 (STAT3). Both NF-B and STAT3 are activated by a variety of 
stimuli (stressors, cytokines, etc.), and while they are regulated by entirely different 
signaling mechanisms, they both control the expression of proliferation-enhancing, anti-
apoptotic, angiogenic, and immune-modulating genes. NF-kB and STAT3 also interact and 
mediate crosstalk between tumor cells and inflammatory cells within the tumor 
microenvironment to promote the development and progression of multiple types of human 
cancers including but not limited to pancreatic, colon, gastric, skin, head and neck, and liver 
cancers (Grivennikov & Karin; Lin et al.; Bromberg et al., 1999; Greten et al., 2004; Yu & Jove, 
2004; Yu et al., 2009).  
NF-B, which is directly activated via the MyD88-dependent branch of TLR signaling, is one 
of the most studied transcription factors and arguably the most important for tumor 
promotion (Chaturvedi et al., 2011). NF-B is constitutively activated in most cancers 
typically due to stimulation of TLRs, pro-inflammatory cytokine receptors (such as TNF- 
and IL-1), and antigen receptors (Dinarello, 1994; Kruglov et al., 2008; Bezbradica & 
Medzhitov, 2009; Karin & Gallagher, 2009). This constitutive activation of NF-B has been 
linked to inflammation, transformation, proliferation, angiogenesis, invasion, metastasis, 
chemoresistance and radioresistance (Beg & Baltimore, 1996; Liu et al., 1996; Van Antwerp et 
al., 1996; Wang et al., 1996; Huang & Miyamoto, 2001; Joyce et al., 2001; Luo et al., 2004; 
Mantovani et al., 2008; Chaturvedi et al., 2011). Activation of NF-B results in the 
upregulation of several genes and cytokines which are associated with cell growth and 
proliferation. These include critical cellular progression genes and anti-apoptotic genes 
including specific inhibitor of caspase 8, c-FLIP29, the caspase inhibitors cIAP1 & cIAP2, the 
anti-apoptotic member of the B-cell leukaemia/lymphoma 2 (Bcl2) family, Bcl-XL BCL2 and 
BCL-XL, c-myc, c-myb. Cyclin D1/2 stimulation by NF-kB activation has also been shown to 
stimulate cell-cycle progression. Many of these together upregulate JNK activity and 
subsequent activation of the AP-1 transcription factor which also enhances cell survival 
(Karin, 2006). Inhibitors of NF-B have been shown to decrease tumor cell proliferation and 
aid in the potency of chemotherapeutics (Luo et al., 2004; Chaturvedi et al., 2011). 
In non-stimulated cells, STAT3 is kept in an inactive form in the cytoplasm (Darnell et al., 
1994; Yu & Jove, 2004). Upon stimulation STAT3 is phosphorylated at two critical residues; 
tyrosine 705 (Tyr705) and serine 727 (Ser727) (Wen et al., 1995; Barboza et al., 2004; Gartsbein 
et al., 2006; Yeh et al., 2006), dimerizes (Yoshimura et al., 2007), and translocates to the 
nucleus where it activates a wide array of genes critical for tumor development and 
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progression. STAT3 is activated by many cytokines, including those cytokines that are 
products of the TLR signaling pathway, including cytokines of the IL-6 family that signal 
through gp130 (IL-6, IL-11, IL-27, etc.), the IL-10 family (IL-10, IL-22, IL-19, IL-20), and the 
epidermal growth factor (EGF) family (VEGF, IL-21, IL-23, HGF). Like NF-B, STAT3 also 
activates anti-apoptotic genes such as Bcl-xL, Bcl-2, and c-IAP2 (Yu & Jove, 2004; Chang et 
al., 2006; Rebouissou et al., 2009), cell cycle and proliferation genes such as Cyclin D1 and c-
Myc (Levy & Darnell, 2002; Naugler & Karin, 2008; Bollrath et al., 2009), and members of the 
AP-1 family such as c-Jun and c-Fos (Hirano et al., 2000; Yang et al., 2005b; Yang et al., 2007), 
whereas others such as Mcl-1 and Survivin are STAT-3-dependent (Yu & Jove, 2004). Thus, 
STAT3 is an attractive target for anti-cancer therapy and numerous strategies have been 
employed to inhibit constitutive STAT3 signaling in cancer cells (Meydan et al., 1996; 
Turkson et al., 2001; Coleman et al., 2005; Song et al., 2005; Duan et al., 2006; Schust et al., 
2006; Iwamaru et al., 2007; Siddiquee et al., 2007; Goel et al., 2008; Hatcher et al., 2008; Lin et 
al., 2010a; Lin et al., 2010b). 
Activator Protein 1 (AP-1) transcriptional complexes also play a pivitol role in malignant 
cellular transformation (Lopez-Bergami et al., 2009). AP-1 can be activated through the TLR 
Myd88-dependent pathway by a variety of growth factors and cytokines (Akira, 2006). 
Increased exposure to environmental carcinogens such as tobacco, nicotine and asbestos 
have been shown to increase AP-1 activity and correlate with tumorgenesis, tumor invasion 
and metastasis (Lopez-Bergami et al., 2009). AP-1 can induce the activation of well-known 
oncogenes including FOS and Jun which are observed in many cancers (Lopez-Bergami et 
al., 2009). The expression of Jun can further activate other oncogenes including Ras, BRAF 
and EGFR. Increased FOS expression has been associated with poor prognosis and 
progression (Lopez-Bergami et al., 2009). Inhibition of AP-1 complexes as well as Jun and 
FOS have been shown to inhibit tumor formation suggesting that AP-1 may be a viable 
target for therapeutic intervention (Lopez-Bergami et al., 2009).  
4.3 Activation of TLR signaling leads to the production of cytokines and upregulation 
of other proteins that control metastasis 
An important effect of inflammation on cancer is the ability to stimulate tumor invasiveness 
and metastasis. This ability depends in part, on activation of TLRs on immune cells and 
cancer cells. The pro-inflammatory microenvironment contributes to shaping the gene 
expression profile that is required for metastatic behavior of cancer cells. 
4.3.1 NF-B 
TLR activation of MyD88, TRAF6, and NF-B in inflammatory cells and tumor cells within 
the tumor microenvironment play a key role not only in cancer development but also in 
tumor progression (Gohda et al., 2004; Greten et al., 2004; Pikarsky et al., 2004; Kaisho & 
Akira, 2006; Inoue et al., 2007). A correlation was found between the amount of tumor 
associated macrophages (TAMs) present in the tumor and prognosis; the higher the density 
of TAMs, the poorer the prognosis (Duncan et al., 1998). TLR-mediated pro-inflammatory 
cytokine production from tumor associated macrophages (TAMs) play a key role in tumor 
progression and metastasis (Gohda et al., 2004; Inoue et al., 2007). For example, activation of 
the TLR-TRAF6- NF-B pathway in tumor associated inflammatory cells, and the 
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subsequent release of pro-inflammatory cytokines from those cells has been shown to result 
in the activation of NF-B in precancerous cells which drives the growth and malignant 
transformation of those cells (Gohda et al., 2004; Inoue et al., 2007). In addition, TLR-
mediated activation of NF-B is necessary for the differentiation and maturation of 
osteoclasts, which drive the resorption of bone and generate a microenvironment ideal for 
tumor cells to proliferate and colonize, thus enhancing bone metastasis of certain types of 
cancer cells, particularly breast cancer cells (Coleman & Rubens, 1987; Sasaki et al., 1995; 
Lomaga et al., 1999; Naito et al., 1999; Kobayashi et al., 2001). Several genes regulated by 
NF-B encode adhesion molecules, MMPs, serine proteases, heparanase, and chemokines 
that have been shown to be important for tumor invasion and metastasis (Karin & Greten, 
2005). Blockade of NF-B activation reduces proliferation, metastatic ability, and enhances 
apoptosis of cancer cells (Nakanishi & Toi, 2005; Inoue et al., 2007). 
4.3.2 TLR4 
TLR4 signaling has been directly implicated in the regulation of cancer cell metastasis. 
Activation of TLR4 signaling in cancer cells by lipopolysaccharide (LPS), an exogenous ligand 
for TLR4, induces synthesis of IL-6, inducible nitric oxide synthase (iNOS), and IL12 p40. This 
effect on cancer cells is similar to what is observed during the activation of macrophages. 
Blockade of the TLR4 pathway has been found to delay tumor growth and prolong survival in 
mice (Huang et al., 2005a). Recently it was demonstrated that LPS increases the invasiveness of 
pancreatic cancer cells and that increases in invasiveness by LPS was hampered by blocking 
the NF-κB signaling pathway. More specifically, the LPS-dependent invasiveness was 
decreased by blocking the TLR4/MyD88/NF-κB signaling pathway, once again connecting 
TLR-mediated inflammation with cancer invasion and progression (Ikebe et al., 2009). In fact, a 
clinical study of 30 cases of pancreatic ductal adenocarcinoma found that TLR4, NF-κB and 
hypoxia-inducible factor 1-alpha (HIF1ǂ) were over-expressed compared to surrounding 
tissues. Survival of patients with an absence of TLR4 expression in tumor tissues was 
significantly longer than those with TLR4 expression (Zhang et al.). 
4.3.3 Wnt5a 
Wnt proteins are a family of secreted glyocoproteins involved in critical cellular processes 
during embryogenesis. Wnt5a is a member of the Wnt family that has been implicated in 
carcinogenesis and inflammation. Non-canonical Wnt5a activates B-catenin-independent 
pathways important for cell migration and polarity.  
Wnt5a has been implicated in pancreatic cancer for many years. A decade ago the gene 
expression of Wnt5a signaling members were found in tissue samples of pancreatic 
adenocarcinomas (Crnogorac-Jurcevic et al., 2001). Wnt5a expression was found to be 
gradually increased in pancreatic intraepithelial lesions and highly expressed in advanced 
pancreatic cancer (Ripka et al., 2007). Despite these associations, the role of Wnt5a in cancer 
remains controversial as some studies show that Wnt5a may work as a tumor suppressor 
while others show an oncogenic effect (McDonald & Silver, 2009). Although the exact role of 
Wnt5a in cancer remains unclear, the expression of Wnt5a in tumor samples has been 
correlated with advanced stages and poor prognosis in gastric, colon, prostate, lung, and 
malignant melanoma (Iozzo et al., 1995; Lejeune et al., 1995; Saitoh et al., 2002; Weeraratna et 
al., 2002; Huang et al., 2005b).  
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In vitro studies have shown that Wnt5a induces cell migration, proliferation and invasion in 
a variety of cancer cell lines (Weeraratna et al., 2002; Kurayoshi et al., 2006; McDonald & 
Silver, 2009), lending support to the hypothesis that Wnt5a may be involved in invasion or 
metastasis of several different cancers. At present the precise mechanisms linking Wnt5a 
with cancer invasion and metastatis are still largely unknown, however recent studies have 
hinted at possible molecular mechanisms. The Ca2+ signaling and subsequent protein 
kinase C (PKC) activation was suggested as the mechanism for enhanced motility and 
invasiveness for malignant melanoma (Weeraratna et al., 2002). In addition, a recent study 
associated polarized cell migration with the Wnt5a-ROR2 signaling pathway (Nishita et al.). 
Wnt5a involvement during EMT in pancreatic cancer was also suggested (Ripka et al., 2007). 
Wnt5a was described as a target of the homeobox transcription factor CULT1, enhancing 
migration, proliferation and invasiveness during pancreatic tumorigenensis (Ripka et al., 
2007).  
An IL-6 / STAT3 / Wnt5a signaling loop has been described by different groups (Katoh, 
2007; McCall et al., 2007). Our group demonstrated that IL-6, a TLR signaling product, can 
activate STAT3 with resulting overexpression of Wnt5a in papillary thyroid carcinoma cells 
and that phenylmethimazole (C10), a derivative of the anti-thyroidal medication 
methimazole, has the ability to block TLR3 signaling, IL-6 production, as well as decrease 
growth and migration of papillary thyroid carcinoma cells (McCall et al., 2007). We 
hypothesized that the C10 effect on growth and migration of the papillary thyroid cancer 
cells was related to its suppressive effect on TLR3 signaling which led to the 
downregulation of TLR-mediated STAT3 and Wnt5a signaling (McCall et al., 2007). This 
was the first study that linked TLR signaling with Wnt5a and cancer cell growth and 
migration. 
More recently our group has shown that TLR3 and Wnt5a RNA are constitutively expressed 
in human pancreatic cancer and malignant melanoma cell lines in culture. In similar 
findings to what we reported in human papillary thyroid cells, C10 inhibits TLR3 expression 
and signaling in addition to growth and migration of these human pancreatic cancer and 
malignant melanoma cells. Moreover, in this report we established in vivo efficacy by 
showing that C10 delays tumor growth in mouse models of human pancreatic cancer and 
malignant melanoma. These studies showed that this phenomenon was also associated with 
inhibition of STAT3 activation (Schwartz et al., 2009). Since STAT3 activation is a strong 
regulator of Wnt5a expression, and since C10 can block migration of these pancreatic and 
malignant melanoma cells in vitro as well as Wnt5a expression and signaling, we suspect 
that C10 may also act to prevent metastasis in vivo. 
4.3.4 Other TLR-related molecules 
Tumor necrosis factor alpha (TNF-), a product of TLR signaling, is a critical cytokine that 
induces expression of other inflammatory mediators and proteases important for tumor 
invasiveness and metastasis. Although at high doses extrinsic TNF- cause hemorrhagic 
necrosis, at low concentrations it acts as an endogenous tumor promoter. It can be produced 
by malignant epithelial cells or stromal cells (Balkwill, 2002). The tumor promotion capacity 
depends on activation of NF-B (Luo et al., 2004; Pikarsky et al., 2004). TNF- 
expression/production is associated with poor prognosis, loss of hormone responsiveness 
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and cachexia (Luo et al., 2004). TNF- increases vascular permeability, can stimulate the 
migration and extravasation or intravasation of cancer cells or can acts as a growth factor 
(Luo et al., 2004). 
TLR signaling products IL-1 and IL-1 in the tumor microenvironment both contribute to 
increased invasiveness and metastasis (Gemma et al., 2001; Elaraj et al., 2011). IL-1 can 
promote metastasis by different mechanisms; first by increasing the adhesiveness of the 
endothelium via VCAM-1 or mannose receptor expression in endothelial cells. A second 
mechanism may involve induction of MMPs, cytokines and chemokines in tumor or stromal 
cells (Anasagasti et al., 1997; Song et al., 2003). A third mechanism is via the induction of 
angiogenic factors such as VEGF and IL-8 (Lewis et al., 2006). In 2003 two groups 
independently established that IL-1 and IL-1 were critical for the invasiveness and 
metastasis of pancreatic cancer and melanoma tumor cells (Sawai et al., 2003; Voronov et al., 
2003). IL-1 is mainly produced by myeloid cells, with intricate transcriptional and post-
transcriptional control. IL-1 increases tumor invasiveness and metastasis by promoting the 
production of angiogenic factors by stromal mononuclear cells (Saijo et al., 2002). IL-1 is 
secreted mainly by epithelial cells undergoing necrosis (Sakurai et al., 2008). In liver it was 
found that IL-1 released by necrotic hepatocytes induces IL-6 synthesis by Kupffer cells 
which activates pro-oncogenic transcription factor STAT3 (Naugler et al., 2007). IL-1 
receptor activation by either form of IL-1 can lead to induction of IL-6. In multiple myeloma 
IL-6 promotes survival and proliferation of cancer cells via activation of STAT3 and 
extracellular signal – regulated kinase ERK signaling (Honemann et al., 2001). IL-6 - STAT3 
signaling was also found in chemically induced liver carcinogenesis as well as many other 
types of cancers (Calo et al., 2003; McCall et al., 2007; Naugler et al., 2007; Schwartz et al., 
2009). 
COX-2, a TLR4 signaling product (Fukata et al., 2006), is highly expressed in a variety of 
cancers such as colorectal, gastric, esophageal, breast and prostate carcinomas. COX-2-
produced prostaglandin E2 (PGE2) increases tumor invasiveness and metastasis and 
enhances production of IL-6, IL-8, VEGF, iNOS, MMP2 and MMP9 among others (Gasparini 
et al., 2003). COX-2 inhibition shows chemopreventive and antimetastatic activity in a 
variety of human cancers through disruption of the inflammatory microenvironment (Baek 
& Eling, 2006). 
TLR-induced TGF-ǃ is produce by myeloid cells, mesenchymal cells and cancer cells in 
hypoxic and inflammatory conditions (He et al., 2007; Ren et al., 2007; Zhou et al., 2009). It is 
one of the most highly expressed cytokines in the tumor microenvironment and has a large 
influence on tumor cell invasiveness and metastasis (Yang et al., 2010). The induction of 
angiopoietin-like 4 (ANGPTL4) in cancer cells by TGF-ǃ disrupts vascular endothelial cell 
cell to cell junctions, increases the permeability of lung capillaries, and facilitates the trans-
endothelial passage of tumor cells (Padua et al., 2008).  
Versican is an aggregating chondroitin sulfate proteoglycan highly expressed in several 
cancers (Pirinen et al., 2005). Versican enhances tumor cell migration, growth and 
angiogenesis (Zheng et al., 2004). Versican has pro-inflammatory activity, it induces 
macrophages activation and stimulates the secretion of TNF- and other cytokines (Wight, 
2002; Kim & Karin, 2011). In addition, versican interacts with several adhesion molecules 
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expressed by inflammatory cells (Wight, 2002) and activates endothelial cells, fibroblasts 
and macrophages in the tumor microenviroment (Wang et al., 2009). Importantly, versican 
activates TLR2 on macrophages to induce NF-B and MAP kinase (MAPK) signaling with 
the subsequent production of pro-inflammatory cytokines such as IL-6 and TNF- (Wang et 
al., 2009). The inhibition of versican expression in LCC cells eliminates their metastatic 
behavior (Kim et al., 2009). In addition, a related proteoglycan, biglycan was found to 
activate macrophages through TLR2 and TLR4 (Schaefer et al., 2005). 
Helix-loop-helix protein Twist, is a key transcription factor that regulates cell movement 
and tissue reorganization during early embryogenesis with a role in the epithelial-
mesenchymal transition (EMT) process during normal development. Suppression of Twist 
in metastatic 4T1 mammary carcinoma cells specifically inhibits their ability to metastasize 
to lung but not their ability to form primary tumors (Yang et al., 2004) and loss of Twist 
expression prevents the entry of metastatic cells into the circulation (Yang et al., 2004). 
Together, these findings suggest that Twist can contribute to invasion and metastasis by 
promoting the EMT developmental program in cancer. Interestingly, Twist expression can 
be induced in response to NF-ĸB activation and is therefore upregulated in response to 
inflammation (Pham et al., 2007). This could be a mechanism through which tumor-
associated inflammation may stimulate metastatic progression through induction of Twist-
dependent EMT (Yang et al., 2004; Pham et al., 2007). 
Another mechanism of cancer invasiveness and metastasis was identified in a metastatic 
prostate cancer model that involves the repression of Maspin. Maspin is a member of the 
serpin family with well-established anti-metastatic activity in breast and prostate cancers. It 
was found that the metastatic behavior of isolated cells was dependent on the activation and 
nuclear accumulation of IKKǂ (Preciado et al., 2005). Repression of Maspin transcription 
required nuclear translocation of catalytically active IKKǂ, which occur only in advanced 
prostate tumors that contain inflammatory infiltrates and cells that express receptor 
activator of nuclear factor kappa-B ligand (RANKL) and LTǂ:ǃ (Preciado et al., 2005). 
RANKL can lead to repression of maspin-expression in an IKKǂ-dependent manner (Zou et 
al., 1994; Luo et al., 2007). Thus, IKKǂ infers its pro-mestastatic effect by repressing 
transcription of the maspin gene. 
Although the molecular mechanisms involved in these metastatic processes seem to be 
complex and not well understood, TLR signaling and related proteins appear to play an 
important role. 
4.4 TLRs have an important role in tumor angiogenesis  
In 1995, Judah Folkman wrote (Folkman, 1995) that “recent discoveries of endogenous 
negative regulators of angiogenesis, thrombospondin, angiostatin, and glioma-derived 
angiogenesis inhibitory factor, all associated with neovascularized tumors, suggest a new 
paradigm of tumorigenesis. It is now helpful to think of the switch to the angiogenic 
phenotype as a net balance of positive and negative regulators of blood vessel growth. The 
extent to which the negative regulators are decreased during this switch may dictate 
whether a primary tumor grows rapidly or slowly and whether metastasis grows at all.” 
Folkman recognized that cancer has the ability to spread to adjacent or distant organs; he 
recognized that tumor cells could penetrate blood or lymphatic vessel walls, spread through 
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the blood or lymphatic vessels to another site, where they could proliferate; but he further 
recognized that the key to the metastatic or tumor growth process was angiogenesis. At that 
time he did not envision the importance of the Toll-like receptor and signal system in 
regulating this switch from normal to pathologically driven angiogenesis. 
Cell growth, cell development, and cell migration, independent of whether immune or non-
immune cell in origin, require blood vessel formation to feed the inflamed areas with 
nutrients and oxygen, particularly chronically inflamed and growing tissues. This is 
reviewed in Grote, et al, whose work can be construed not only as an important component 
of the following discussion but the “bible” on which it is based (Grote et al., 2011). Vascular 
growth is termed angiogenesis or vasculogenesis. Angiogenesis is the formation of new 
blood vessels by sprouting or by intussusception of preexisting vessels; vasculogenesis 
defines a process whereby progenitor cells differentiate into endothelial cells (Ribatti, 2010). 
Both processes often occur together and are often termed neovascularization, as for example 
in atherosclerotic lesions. 
Tumor angiogenesis is a multistep process (Nishida et al., 2006). Simplistically, first the 
basement membrane in tissues is injured locally with resultant tissue destruction and 
hypoxia. Second, endothelial cells activated by angiogenic factors migrate into the damaged 
area. Third, endothelial cells stimulated by angiogenic factors proliferate and stabilize. Then, 
angiogenic factors continue to influence tissue nutrient supply and waste removal. It is 
intuitive that this is not a simple process and must be highly controlled (Carmeliet, 2000).  
One example of this is the role of hypoxia in tumor angiogenesis. The irregular pattern and 
organization of the tumor vasculature result in some cells being more than 100 μm from a 
blood vessel, the accepted diffusion limit for oxygen. Progressive hypoxia with distance 
from the oxygen source results in induction in hypoxia-inducer factor 1 alpha (HIF-1ǂ) and 
1 beta (HIF-1ǃ) and, upregulated gene expression (VEGF, Ang2, iNOS, PDGF-B), increased 
glycolysis, and stimulation of angiogenesis.  
Secondly, blood vessels have endothelial cell walls, a media composed of fibroblasts, fat 
cells, collagen molecules, and mesenchymal tissue, and a surrounding smooth muscle and 
epithelial cell layer in arteries or just an epithelial cell layer in non arterial vasculature. 
Blood vessels form in a regular pattern as part of a normal vascular network but in a 
disordered array in chronic inflammatory states or cancer. In examining angiogenesis, one 
must thus consider multiple cell types, multiple coordinated interactions, and complex 
regulatory networks. 
The complexity is evidenced molecularly (Carmeliet, 2000; Olsson et al., 2006). VEGF 
(vascular endothelial growth factor) is now recognized to be 5 VEGF ligands (A-D) in 
different spliced or processed variants, yet each is a dimeric glycoprotein of about 40K. 
Placenta growth factor (PLGF) is also a family member. They bind to 3 receptor tyrosine 
kinases (VEGFR 1-3) which can have an overlapping functional pattern, and can have 
multiple co-receptors, including neuropilins, proteoglycans, and heparin-sulfate. Each 
VGFR has a different function: VEGFR1 is important in hematopoetic progenitor cell 
recruitment; it also regulates monocyte migration; VEGFR2 and 3 control endothelial cell 
function during angiogenesis. Lest this complexity overwhelm us, Tie receptors and their 
angiopoitin (Ang) ligands are a second endothelial cell-specific receptor tyrosine kinase 
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system which interacts with the VEGF-VEGFR kinase system during angiogenesis (Partanen 
et al., 1992; Augustin et al., 2009). Ang-Tie interactions normally control signals leading to 
vessel quiescence and the last steps of vessel maturation. 
Capillaries develop and grow with a VEGF gradient. Endothelial cells at the leading edge of 
the capillary tube, tip cells, have filopodia and express multiple VEGFR family members. 
“Behind them” in the advancing gradient of growth and development are highly 
proliferative, differentiating “stalk” cells and resting cells expressing components of the 
Ang-Tie system. A key component regulating the “sprouting” tip cells vs stalk cells is the 
Delta/Notch Signaling system (Gridley, 2010). Again complexity exists. There are 4 different 
Notch Receptors, Notch 1-4. Notch receptors have a single transmembrane domain binding 
to membrane ligands Delta-like (Dll) 1-4 and Jagged. Notch signaling in stalk cells induces a 
quiescent endothelial cell phenotype whereas TIP cells enriched in DLL4 promote sprouting 
activity and capillary growth (Gridley, 2010). Other factors in associated cells, such as basic 
fibroblast growth factor (bFGF) and platelet derived growth factor (PDGF) control 
“endothelial cell coverage” by pericytes and smooth muscle cells to establish vasculature 
stability and maturation (Distler et al., 2003).  
In sum, the regulated action of a multiplicity of angiogenic factors and receptor kinases 
control capillary sprouting, growth, differentiation (e.g., tip vs stalk) and endothelial cell 
“coverage” and “stabilization.” Moreover this list does not even consider a multiplicity of 
cytokines, chemokines, and growth factors with pro-angiogenic importance (Bussolino et al., 
1991). Together, these, plus controlling inhibitory factors such as angiostatin, define a 
balanced pro- or anti-angiogenic system in normal tissues. It is now accepted that the 
“angiogenic switch” is “off” when the effect of pro-angiogenic molecules is balanced by that 
of anti-angiogenic molecules and is “on” when the net balance is tipped in favor of 
angiogenesis. A list of angiogenic stimulators and angiogenic inhibitors was summarized in 
“Angiogenesis in cancer and other disease” an Insight Review Article by Peter Carmeliet 
and Rakesh Jain (Carmeliet & Jain, 2000). This multiplicity is much expanded now, and 
offers an array of targets to stimulate angiogenesis, for example after a myocardial infarction 
(Vandervelde et al., 2005), or to inhibit angiogenesis to control dysregulated cell growth 
precipitated by chronic inflammation, for example in cancer, atherosclerosis, or obesity-
induced diabetes (Cao, 2009). A VEGF-neutralizing monoclonal, anti-TNF-ǂ, is one of many 
therapies targeting single gene products in this complex cascade. Of interest, numerous 
individual specific antibodies and inhibitors of specific tyrosine kinases have been evaluated 
in the past 10-15 years; however, not surprisingly, this approach has had limited success in a 
complex, interrelated, redundant signal system/pathway. 
4.4.1 Inflammation and angiogenesis 
Accumulating evidence supports a link between inflammation and angiogenesis. The two 
processes are intimately intertwined in inflammation-associated wound healing and tissue 
regeneration. Thus, the acute gene response set off by the innate immune process results in 
cytokines, chemokines, and growth factors produced at the site of the injury, which not only 
induce inflammation but also successive tissue repair. Angiogenesis is an important 
component of this tissue repair as evidenced by increased expression of VEGF. The 
inflammation-induced wound healing includes, in addition, pro-angiogenic factors such as 
basic fibroblast growth factor (bFGF), TGF-ǃ, TNF-ǂ, insulin-like growth factor-1 (IGF-1), 
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monocyte chemotactic protein-1 (MCP-1), IL-6 and IL-8, PDGF, to name but a few, which 
attract endothelial cells, smooth muscle cells, and epithelial cells needed for vessel growth 
and maturation.  
Chronic inflammation leading to different pathological states, such as obesity-induced 
diabetes, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, and cancer, 
nevertheless have a common gene activation process and angionesis component. That 
chronic inflammation leads to diverse pathologic states involving the same molecular events 
should not be a surprise if one recognizes the commonality of inflammation and wound 
repair in all tissues, despite their varied differentiated states. Organ specific diseases do not 
negate common mechanisms of wound repair and angiogenesis in each. 
4.4.2 Toll-like receptor signaling in inflammation and angiogenesis 
To date, most studies linking TLR signaling to angiogenesis are in vitro and are largely 
descriptive. Thus, there is literature describing the use of several TLR agonists to induce 
expression and secretion of multiple angiogenic factors in an array of different cell types in 
vitro. The majority, however use LPS to stimulate TLR4 signaling with increased VEGF as a 
marker of angiogenesis.  
1. LPS activation of TLR4 signaling in vitro increases adenosine promotion of angiogenesis 
through the A2A Receptor system to increase VEGF (Hara et al., 2009). This cardio-
protective nucleoside stimulates angiogenesis by increasing VEGF in macrophages, 
thereby likely offering tissue protection after ischemic injury. Moreover, there is a 
synergistic down-regulation of TNF-ǂ (Leibovich et al., 2002). This angiogenic “switch” 
was noted also with TLR2, TLR7, and TLR9 agonists (Pinhal-Enfield et al., 2003). There 
is an in vivo correlate, since MyD88-deficient mice had decreased generation of new 
capillaries in response to an A2AR agonist (Macedo et al., 2007). 
2. LPS-increased TLR4 signaling was shown to increase endothelial sprouting in vitro via a 
TRAF6, NF-κB, JNK stimulatory process (Pollet et al., 2003). The requirement for TRAF6 
in vitro and in vivo was established using a retrovirally expressed dominant negative 
TRAF6 in endothelial cells (Pollet et al., 2003). Moreover, inhibition of c-Jun N-terminal 
kinase (JNK) activity or NF-κB activity downstream of TRAF6 inhibited LPS-induced 
endothelial sprouting. Inhibition of only NF-κB but not JNK activity blocked bFGF, not 
TRAF6 induced angiogenesis. In sum, a direct endothelial role of TLR4 activation via 
TRAF6 is important in inducing angiogenesis in endothelial cells (Pollet et al., 2003). 
This has a pathologic counterpart in pathological corneal neovascularization that can 
cause impaired vision when induced by infections wherein TLR4 and VEGF are 
increased (Rodriguez-Martinez et al., 2006).  
3. Bactonella henselae infections increase MCP-1 in endothelial cells, which chemotactically 
attracts monocytes to produce VEGF and increase angiogenesis (McCord et al., 2005). 
This is an NF-κB dependent process independent of TLR4 or LPS. 
4. The TLR4/MyD88 signal system is important in VEGF production and angiogenesis in 
liver endothelial cells stimulated with LPS (Jagavelu et al., 2010). 
5. Mycoplasma infections of the pulmonary tract causing a chronic inflammatory process 
increase angiogenesis and vascular remodeling (McDonald, 2001). This appears to be 
associated with a TLR2/6-dependent induction of NF-κB and a MAPK cascade by a 2 
kDa macrophage activating diacylated lipopeptide (MALP-2) present in the 
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mycoplasma and secretion of GM-CSF from endothelial cells and monocytes. MALP-2 
induced angiogenesis in vitro and in vivo is suppressed by GM-CSF, explaining both 
angiogenesis and remodeling in the same tissues.  
6. Increased VEGF in chondrocytes and VEGF and IL-8 in fibroblasts are associated with 
inflammatory cell induced angiogenesis in chronically inflamed joints associated with 
arthritis. This progressive self-destructive angiogenic process involves a peptidoglycan 
(PGN) TLR2 ligand from Gram-positive bacteria (Cho et al., 2007).  
4.4.3 Toll-like receptor signaling in tumor angiogenesis 
Cancer is associated with, or induced, by chronic inflammation. Nevertheless, a clear 
definition of TLR induced angiogenesis varies because of the diversity of cancers and 
incomplete studies of all.  
In gastric cancer linked to chronic H. pylori infections, cyclooxygenase 2 (COX-2) plays a 
critical role. Thus, H. Pylori activation of TLR2 and TLR9 signals activate the MAPK cascade 
leading to increased COX-2 and COX-2-dependent prostaglandin E2 (PGE2) release. This 
contributes to cancer cell invasion and angiogenesis (Chang et al., 2005). The COX-2 increase 
can be attenuated by the specific COX-2 inhibitor, NS398 or celecoxib. The cAMP response 
element (CRE) and AP-1 sites, but not NF-κB on the COX-2 promoter, are involved in 
MAPK-regulated COX-2 expression. Differential binding of CREB-1, ATF-2, and c-jun to the 
CRE site and c-fos, c-jun, and ATF-2 to the AP1 site were demonstrated and attenuated by 
different MAPK inhibitors as well as mutants of TLR2 and TLR9. In sum, these results 
showed that H. pylori activated TLR2 and TLR9 to activate MAKs, particularly p38, and 
downstream transcription factors (CREB-1, ATF-2, c-jun, and c-fos) resulting in activations 
of CRE and AP-1 on the COX-2 promoter (Chang et al., 2005). 
Sustained pro-inflammatory processes in cancer, as well as diabetes, atherosclerosis, and 
rheumatoid disease are associated with increased angiogenesis and disease progression. 
Necrotic cells release high mobility group B1 (HMGB1), a pro-inflammatory cytokine, 
which signals TLR2 and TLR4 and the receptor for advanced glycation end products 
(RAGE) to increase angiogenesis by up-regulating NF-κB and VEGF in hematopoietic cells 
and endothelial cells (van Beijnum et al., 2008). HMGB1 seems to be involved in a positive 
feedback mechanism that sustains inflammation and angiogenesis contributing to disease 
progression. Endothelial cells express HMGB1 as well as RAGE receptors, TLR2 and 
TLR4. The HMGB1 can increase NF-κB activity, which can, in turn, increase HMGB1 
receptors.  
Inflammation-induced oxidative stress and angiogenesis are a common theme in tissue 
regeneration and remodeling in cancers. End products of lipid oxidation, such as ω-(2-
carboxyethyl)pyrrole (CEP), are generated, accumulate, and are recognized by TLR2 in 
endothelial cells, leading to a MyD88-dependent angiogenic responses independent of 
VEGF (West et al., 2010). These endogenous ligands accumulating during cancer-induced 
tissue disruption promote angiogenesis via a TLR-dependent pathway. Grote, et. al., 
summarize this visually in Figure 4 of their review (Grote et al., 2011). 
Nevertheless, a counter-regulatory TLR path can be activated as well, which inhibits 
angiogenesis and cancer progression. For example, the immune-modulatory TLR9 agonist, 
IMO, inhibits micro-vessel formation and cancer growth (Damiano et al., 2006). Similarly the 
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TLR7 agonist imidazoquinoline and the TLR9 agonist un-methylated cytosine- phosphate-
guanosine (CpG) oligonucleotide exhibit strong local activity against leukemia in Phase I/II 
trials at different centers (Spaner & Masellis, 2007). Their importance appears, however, to 
be to sensitize CLL cells to other cytotoxic agents so any future lies with combined 
chemotherapy, radiotherapy, or other more “toxic” agents. 
Resistance to anti-HER2 monoclonal antibody, trastuzumab is an issue in breast cancer 
patients. The novel Toll-like receptor 9 (TLR9) agonist termed IMO, immune modulatory 
oligonucleotide, potentiates the anti-EGFR/HER2 signaling of monoclonal trastuzumab. It 
modulates a functional interaction between TLR9 and HER receptors at a membrane level, 
producing a cooperative antiangiogenic effect (Damiano et al., 2009).  
In skin cancer, strategies to inhibit neovascularization and angiogenesis include blockade of 
COX-2, m-TOR, sonic hedgehog, growth factor receptor activation, and activation of TLR by 
imiquimod (Li & Li, 2008). Separately, Myricetin, a phytochemical from onions, berries and 
red wine, suppresses ultraviolet (UV) B-induced angiogenesis by inhibiting PI-3 kinase 
activity in vivo in mouse skin. The chronic UVB exposure induced neovascularization that is 
associated with increased VEGF, matrix metalloproteinase (MMP)-9 and MMP-13 
expression. The myricetin inhibited UVB-induced hypoxia inducible factor-1ǂ expression. 
The myricetin effect was associated with attenuation of UVB-induced PI-3kinase activity 
and phosphorylation of Akt/p-70(S6K) (Jung et al., 2010). 
The complexity of TLR3 action in individual tumors with both increased and decreased 
angiogenic activity was suggested in vitro by Paone, et al. (Paone et al., 2010). These authors 
had shown TLR3 activation in LNCaP and PC3 lines, with more efficiency in the former cells 
from a less aggressive tumor. They subsequently describe novel pro-tumor machinery. 
Triggered by TLR3 activation by polyI:C in PC3 cells, they show increased expression of the 
specific 1.3 isoform of HIF-1 alpha and nuclear accumulation of this complex in PC3 cells 
with decreased apoptosis and in secretion of functional VEGF. This is not the case in less 
aggressive LNCaP cells. However, in both cell lines, transfection of the 1.3 isoform of HIF-1 
alpha causes decreased apoptosis and increased secretion of functional VEGF. They suggest 
basal levels of the 1.3 isoform of HIF-1 alpha distinguish differential responses to TLR 
activation. 
In sum, the role of TLR in inducing signaling to increase tumor growth and angiogenesis is 
clear but largely poorly defined. Nevertheless, Grote et al. and others (Chang et al., 2005; 
Spaner & Masellis, 2007; Damiano et al., 2009) suggest that future modulation of TLR 
signaling could be the basis for a therapeutic approach to cancer and inhibition or control of 
abnormal angiogenesis to limit tumor growth. However, this is potentially difficult because 
not only are there TLR-induced pro-angiogenic signals but also anti-angiogenic signals. 
Moreover, the different cells interacting in the process present a complex network to control. 
Trials of anti-VEGF monotherapy provide a caution as well (Freedman et al., 2002; Henry et 
al., 2003) since they have not yielded consistent beneficial results. It is now recognized that 
not one (VEGF) but a multiplicity of potent angiogenic factors act in concert with VEGF for 
proper vessel formation and maturation (Augustin et al., 2009; Gridley, 2010). Rather than a 
unique anti-angiogenic “bullet,” what may be needed is a broadly acting agent acting on a 
multiplicity of cells and a multiplicity of steps in the TLR stimulated cascade as in the case 
of diabetes.  
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5. TLR Involvement in pancreatic cancer 
Toll-like receptors were first implicated in the pathogenesis of pancreatic cancer in 2009 in 
two separate reports. First, TLR3 was first described by our laboratory to play a role in the 
regulation of pancreatic cancer growth and migration. In this report we demonstrated that 
TLR3 and Wnt5a were coordinately constitutively expressed in a human pancreatic cell line 
(PANC-1) derived from a human pancreatic ductal adenocarcinoma, and that 
phenylmethimazole (a TLR signaling inhibitor) inhibits growth and migration of these 
pancreatic cancer cells in cell culture and inhibits pancreatic cancer tumor growth in vivo in 
a nude (nu/nu mice, which lack T cells) mouse model of human pancreatic cancer (Schwartz 
et al., 2009). In a separate 2009 report, Ikebe et. al., showed that LPS activation of the 
TLR4/MyD88 signaling pathway increases the invasive ability of PANC-1 and Aspc-1 
(another pancreatic cancer cell line derived from a human pancreatic ductal 
adenocarcinoma) cells, while blockade of TLR4, MyD88, or NF-kB signaling decreases the 
LPS-dependent increased invasive ability (Ikebe et al., 2009). Together, these studies were 
the first to implicate TLR expression and signaling in pancreatic cancer cells as playing a 
role(s) in pancreatic tumor growth and migration. These studies helped establish that TLR 
expression and signaling in the pancreatic cancer cells (i.e. non-immune cells) themselves 
may be an important contributor to disease development, an idea that is now widely 
accepted for a multitude of autoimmune/inflammatory diseases including cancer. As briefly 
mentioned earlier, clinical relevance of these findings has recently been noted in a study that 
investigated the expression and clinical relevance of TLR4, NF-B, and hypoxia-inducible 
transcription factor- (HIF-1) in pancreatic adenocarcinoma (Zhang et al., 2010). In this 
study, TLR4 and HIF-1 expression was measured via real time polymerase chain reaction 
(PCR) in 30 cases of pancreatic ductal adenocarcinoma and its adjacent tissues, and TLR4, 
NFB, p65, and HIF-1 protein expression was measured by immunohistochemistry in 65 
cases of pancreatic ductal adenocarcinoma and 38 cases of corresponding adjacent tissues. In 
addition, the relationship between TLR4 or HIF-1 and pathologic features, and the 
association between TLR4 and HIF-1were also analyzed. The Kaplan-Meier method was 
used to assess the impact of expression of TLR4 and HIF-1 on survival of the patients with 
pancreatic cancer. Results of these analysis revealed that TLR4, NF-B, and HIF-1 are all 
overexpressed in pancreatic adenocarcinoma, that TLR4 may regulate HIF-1 expression, 
and that TLR4 and HIF-1 act synergistically to promote the development of pancreatic 
adenocarcinoma.  
6. TLRs as potential therapeutic targets for pancreatic and other cancers 
The therapeutic use of TLR agonists has been investigated in several cancer models. The 
rationale for inducing TLR signaling in a tumor setting is that: (a) TLR signaling will target 
tumor cells, inducing apoptosis or inhibiting the generation of factors that augment tumor 
growth or, (b) TLR signaling will enhance a resident or therapy-driven antitumor immune 
response that will eventually lead to tumor cell destruction. At present, mixed results have 
been obtained using TLR agonists against different TLRs. For example, with respect to the 
effect of TLR agonists on tumor cells, it has been shown in mouse breast xenograft cancer 
models that the antitumor effect of TLR3 agonists was dependent on the expression of TLR3 
receptors in tumor cells, and that dsRNA treatment improved outcomes in patients 
harboring TLR3-positive breast tumors (Salaun et al., 2011). Similarly, CpG treatment was 
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able to trigger tumor cell death in human neuroblastoma cells, and tumor-targeted delivery 
of this TLR9 agonist increased survival in a xenograft model of mouse neuroblastoma 
(Brignole et al., 2010). In human patients harboring low-grade B-cell lymphoma, when CpG 
was delivered intratumorally in combination with radiotherapy almost 50% of the patients 
showed complete regression (Brody et al., 2010). CpG molecules were able to interact with 
the transformed B cells that express TLR9 receptors. 
Treatment with TLR agonists has also shown to induce an antitumor response by either 
enhancing dendritic cell (DC) vaccination or T cell adoptive therapies. For example, tumor-
localized delivery TLR agonists such as poly(I:C) or CpG combined with adoptive transfer 
immunotherapy was effective to control tumor growth in an established model of 
aggressive murine B16F10 melanoma(Amos et al., 2011). In particular, it is proposed that 
TLR agonists enhance T cell adoptive therapy by inducing a better interaction of these cells 
with activated resident DCs and by augmenting the activity of these T cells through IFNǄ 
induction (Amos et al., 2011). TLR agonists have also been proposed as adjuvants for DC 
antitumor vaccination. In particular, TLR agonists have been shown to enhance the efficacy 
of DC vaccines in mouse models of melanoma and brain tumors (TLR7/8 agonist) (Prins et 
al., 2006; Ma et al., 2010), sarcoma (TLR3/9 agonists) (Zheng et al., 2008); or lung tumors 
(TLR9)(Cho et al., 2009) among others. 
On the other hand, it has also been shown that TLR agonists can promote cancer cell 
survival and migration, and tumor progression. For example, TLR agonists have been 
shown to increase tumor viability and metastasis of human lung cancer cells (TLR7/8) 
(Cherfils-Vicini et al., 2010); proliferation of human myeloma cells (TLR3) (Chiron et al., 
2009); adhesion and metastasis of human colorectal cancer cells (TLR4) (Hsu et al., 2011); 
and migration of human glioblastoma (TLR4) or human breast cancer cells (TLR2) 
(Thuringer et al., 2010).  
We considered that these contradictory results are due to the complex nature of the tumor 
microenvironment. Tumors are more than cancer cells; they are also composed of non-
tumor cells and the extracellular matrix. In particular, in pancreatic cancer the tumor 
microenvironment is composed of endothelial cells, leukocytes (lymphocytes, macrophages, 
dendritic cells, mast cells and neutrophils), mesenchymal cells (stellate cells and fibroblasts), 
neural cells and an extracellular matrix rich in fibronectin, collagen and periostin (Farrow et 
al., 2008; Erkan et al., 2011). These components of the tumor microenvironment often 
support tumor cell growth, or suppress immune responses against tumor cells. For example, 
stellate cells mediate fibrosis by generating high amounts of extracellular matrix 
components (Masamune et al., 2009), while fibroblasts release hepatocyte growth factor (Xu 
et al., 2010) facilitating tumor cell proliferation. Similarly, macrophages generate cytokines 
and growth factors (Pinhal-Enfield et al., 2003) that stimulate both tumor cell proliferation 
and angiogenesis. However the tumor microenvironment can also hamper therapeutic 
efforts. In addition, the nature of the tumor endothelium can prevent the delivery of 
antitumor factors within the tumor as has been previously shown for ovarian cancer 
(Buckanovich et al., 2008). In the same way, the presence of tumor-associated regulatory T 
cells or myeloid derived suppressor cells can render attempts to generate a powerful 
antitumor immune response by therapeutic vaccination ineffective (Whiteside, 2008).  
Interestingly, although both tumor cells and tumor-associated leukocytes can express TLR, 
their signaling can induce the generation of different molecules (Palha De Sousa et al., 2010). 
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Thus, TLRs are present both in tumor cells and leukocytes, but may have different activities. 
Further, the signaling pathway may be not the same among different leukocyte populations 
such as T cell or antigen presenting cells. Indeed, TLR signaling on mast cells (Oldford et al., 
2010) or Tregs cells (Zhang et al., 2011) may contribute to tumor inhibition, while TLR 
signaling on macrophages can contribute to tumor progression (Pinhal-Enfield et al., 2003). 
Thus there are diverse effects that TLR signaling can induce on different cells within the 
tumor microenvironment. Together, this data argues for specific targeting of tumor 
microenvironment components when applying TLR agonist therapies for cancer. For 
example, TLR agonists can be prepared for their delivery to particular cells within the tumor 
microenvironment (Bourquin et al., 2010). This type of strategy was successfully used to 
activate tumor-associated DCs in ovarian cancer, promoting antitumor immune response in 
vivo (Cubillos-Ruiz et al., 2009; Scarlett et al., 2009).  
On the other hand, the use of TLR antagonists may prove beneficial for those tumors in 
which the tumor microenvironment promotes tumor cell survival and metastasis upon TLR 
signaling. TLR antagonists might also decrease the levels of activation of stromal cells, such 
as tumor-associated macrophages. Macrophages express an array of TLRs and are able to 
produce several growth factors via TLR signaling (Pinhal-Enfield et al., 2003). Moreover, 
abrogation of TLR-4 signaling in tumor-associated macrophages was able to decrease tumor 
growth (Lee et al., 2009). In particular for pancreatic cancer, it has been shown that TLR3 
and TLR4 signaling promotes the invasiveness of pancreatic tumor cells (Ikebe et al., 2009). 
In this context, our recently published manuscript showing that C10 inhibited tumor growth 
in an in vivo model of pancreatic cancer highlights the relevance of using TLR antagonists 
for tumor therapies (Schwartz et al., 2009). Since C10 abrogates both TLR3 and TLR4 
signaling (Schwartz et al., 2009; McCall et al., 2010), this molecule will be extremely relevant 
as a novel therapeutic agent for the treatment of those cancers whose microenvironment 
induces tumor progression via TLR signaling. 
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